S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

$0.89
+0.07 (+8.53%)
(As of 03/1/2024 ET)
Today's Range
$0.77
$0.97
50-Day Range
$0.89
$4.00
52-Week Range
$0.95
$13.23
Volume
247,329 shs
Average Volume
473,083 shs
Market Capitalization
$9.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

YMTX stock logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

YMTX Stock Price History

YMTX Stock News Headlines

Cara Therapeutics Inc CARA
Yumanity Therapeutics Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
See More Headlines
Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
3/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-39,500,000.00
Net Margins
-660.61%
Pretax Margin
-660.61%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Book Value
$2.28 per share

Miscellaneous

Free Float
9,504,000
Market Cap
$9.67 million
Optionable
Not Optionable
Beta
0.32
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Richard Peters M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $896.1k
  • Dr. Vikram Khurana M.D.
    Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology
  • Ms. Chee Yeun Chung Ph.D.
    Scientific Co-Founder & Associate Director of Discovery Biology
  • Ms. Marie Epstein CPA
    VP of Fin.
  • Mr. Michael D. Wyzga (Age 33)
    SVP, CFO & Treasurer
  • Mr. Devin Whittemore Smith (Age 54)
    SVP, Gen. Counsel & Sec.














YMTX Stock Analysis - Frequently Asked Questions

How have YMTX shares performed in 2024?

Yumanity Therapeutics' stock was trading at $3.63 on January 1st, 2024. Since then, YMTX shares have decreased by 75.5% and is now trading at $0.8910.
View the best growth stocks for 2024 here
.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMTX) was last updated on 3/2/2024 by MarketBeat.com Staff